MUMBAI - Pfizer India head Kewal Handa might be faced with a peculiar situation - that of recruiting hundreds of additional staff while his counterparts are given a rather awkward task of cutting employees who have become redundant due to the duplication of portfolios
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
